Seeking Alpha

Stan The Man

 
View as an RSS Feed
View Stan The Man's Comments BY TICKER:
Latest  |  Highest rated
  • Report: Apple shutting down Beats Music (updated) [View news story]
    Regarding the 10 million number... (1) Does it include resales by ATT and other vendors or only represent direct sales by Apple, and (2) Has Apple announced how many more have been ordered that are awaiting delivery? I ordered an iPhone 6+ at ATT the first day and their estimated delivery date is still early November (!).
    Sep 22 04:20 PM | Likes Like |Link to Comment
  • A Repudiation Of Advance Cell Technology's 'Whisper' Results [View article]
    Here is the abstract of the paper from 2012 in Lancet (of a study funded by ACT)

    //////////

    The Lancet, Volume 379, Issue 9817, Pages 713 - 720, 25 February 2012 <Previous Article|Next Article>
    doi:10.1016/S0140-6736... or Link Using DOI
    This article can be found in the following collections: Cardiology & Vascular Medicine (Cardiology & vascular-other)
    Published Online: 24 January 2012
    Copyright © 2012 Elsevier Ltd All rights reserved.
    Embryonic stem cell trials for macular degeneration: a preliminary report

    Prof Steven D Schwartz MD a Corresponding AuthorEmail Address, Jean-Pierre Hubschman MD a, Gad Heilwell MD a, Valentina Franco-Cardenas MD a, Carolyn K Pan MD a, Rosaleen M Ostrick MPH a, Edmund Mickunas MS b, Roger Gay PhD b, Irina Klimanskaya PhD b, Dr Robert Lanza MD b Corresponding AuthorEmail Address
    Summary

    Background
    It has been 13 years since the discovery of human embryonic stem cells (hESCs). Our report provides the first description of hESC-derived cells transplanted into human patients.
    Methods
    We started two prospective clinical studies to establish the safety and tolerability of subretinal transplantation of hESC-derived retinal pigment epithelium (RPE) in patients with Stargardt's macular dystrophy and dry age-related macular degeneration—the leading cause of blindness in the developed world. Preoperative and postoperative ophthalmic examinations included visual acuity, fluorescein angiography, optical coherence tomography, and visual field testing. These studies are registered with ClinicalTrials.gov, numbers NCT01345006 and NCT01344993.
    Findings
    Controlled hESC differentiation resulted in greater than 99% pure RPE. The cells displayed typical RPE behaviour and integrated into the host RPE layer forming mature quiescent monolayers after transplantation in animals. The stage of differentiation substantially affected attachment and survival of the cells in vitro after clinical formulation. Lightly pigmented cells attached and spread in a substantially greater proportion (>90%) than more darkly pigmented cells after culture. After surgery, structural evidence confirmed cells had attached and continued to persist during our study. We did not identify signs of hyperproliferation, abnormal growth, or immune mediated transplant rejection in either patient during the first 4 months. Although there is little agreement between investigators on visual endpoints in patients with low vision, it is encouraging that during the observation period neither patient lost vision. Best corrected visual acuity improved from hand motions to 20/800 (and improved from 0 to 5 letters on the Early Treatment Diabetic Retinopathy Study [ETDRS] visual acuity chart) in the study eye of the patient with Stargardt's macular dystrophy, and vision also seemed to improve in the patient with dry age-related macular degeneration (from 21 ETDRS letters to 28).
    Interpretation
    The hESC-derived RPE cells showed no signs of hyperproliferation, tumorigenicity, ectopic tissue formation, or apparent rejection after 4 months. The future therapeutic goal will be to treat patients earlier in the disease processes, potentially increasing the likelihood of photoreceptor and central visual rescue.
    Funding
    Advanced Cell Technology.
    Sep 22 12:10 PM | Likes Like |Link to Comment
  • A Repudiation Of Advance Cell Technology's 'Whisper' Results [View article]
    As noted in my previous post, above, there has been extensive coverage in the UK about a man treated successfully for Stargardt's disease, a genetic form of macular degeneration that strikes young people. I just looked again on Google, and found multiple articles from 2012 and 2013 on this man (named Marcus Hilton, from Wakefield, UK), aged 34 in 2012. There is even a video of him puttering around his kitchen and making himself coffee, with no apparent visual disability. He reportedly started losing his eyesight at age 7 and was diagnosed with Stargardt's at age 10.

    One of the press articles refers to a report of the work published in Lancet, presumably in the 2012-2013 timeframe. Anyone know about that paper?
    Sep 22 12:05 PM | Likes Like |Link to Comment
  • A Repudiation Of Advance Cell Technology's 'Whisper' Results [View article]
    Seems to me like a jargon-filled hatchet job, by a commentator (1) not technically trained to evaluate opthalmology procedures and studies, (2) citing one 2009 article which may or may not be relevant, and (3) relying on one patient's son's supposedly accurate Facebook post?

    What about the 40-something-year-old British Stargards patient who recovered his eyesight through this stem cell therapy (the one that we know about so far through extensive media coverage)? Was his retina restored by removing a cataract as well?

    Seems counterintuitive that AMD has persisted as a major cause of blindness for so many people, if the "cure" for the condition is cataract surgery. To say the least. That proposition sounds to me stupid beyond belief.

    Lets give Dr. Lanza, and the panel of ophthalmologists involved in this trial, and the new Scientific Board the company just created, credit for knowing more about this than the poster. And lets not forget this Phase I study was not designed to prove the efficacy of the therapy, but rather to test and prove safety. If the results are sufficiently good to also show efficacy as well, that would be wonderful.

    As to the future capital needs of the company, that could be said as well about every single company doing a Phase I study that doesn't already have a product for sale. All today's giant success stories were there once as well. Regeneron, for example. The fact that they raised capital did not diminish the astronomical returns eventually delivered to investors who stayed the course.

    Every time I read some misguided post on Yahoo or Seeking Alpha that bashes this company without any new or real basis (like previous hysterical anti-stock-split posts), I wonder why these bashers don't just go away if they dislike this investment? JMY Investments doesn't give a name but describes himself as handling family investments with a "value" orientation. Huh? Just go away if you don't like the company's prospects. This company won't be paying a dividend anytime soon.

    We should know very soon now (the company has said by year end, I think) what the study results actually say. The company has traded mostly around 7 cents the past year ($7.00 post split) but lately has pushed up from there a bit. If the study results are as hoped the stock will FLY. Anyone who sells at $8 will be kicking himself when the stock goes straight up to $40 or $50 on good results.
    Sep 20 04:32 PM | 20 Likes Like |Link to Comment
  • Update: Advanced Cell Technology Conference Call [View article]
    They still need to get shareholder approval again if they don't do it before September 14. Too bad. Seems like they could have just made that date later the first time and not needed to spend money on it again.
    Aug 14 10:56 AM | Likes Like |Link to Comment
  • Update: Advanced Cell Technology Conference Call [View article]
    I liked the fact that Dr. Lanza was on the call, and I found his comments encouraging. When the Phase I results are finally reported, he could make the rounds of the talk shows and become (more of) a worldwide celebrity.
    Aug 12 02:13 PM | Likes Like |Link to Comment
  • How To Value Advanced Cell Technology As A Phase II Company [View article]
    I was glad they scheduled that call.

    Granted there was nothing new, but it was nice to hear Dr. Lanza talk encouragingly about the company's technology and make the points that the applications are limitless but that the immediate focus on AMD and Stargards addresses a huge market, a way to generate some early profits, and a strategic way to demonstrate the technology with regard to a safer entry point (eyes) to the body. (At least that was my takeaway from what he said.)
    Aug 12 10:42 AM | Likes Like |Link to Comment
  • How To Value Advanced Cell Technology As A Phase II Company [View article]
    You state:

    "What this means is that, unless some majority shareholder(s) could be found, no reasonable company is going to attempt to buy ACT outright because they would have to do so on the open market, and that effort would face constantly diminishing return on investment. The only remaining option is to cut a deal whereby ACT gives the rights to all or a portion of its future sales in return for capital and other help in bringing its stem cell treatment to market. So for example, if that wound up being 50/50, we would only expect ACTC shares to be worth about 75 cents each."

    //////

    I'd be happy with "only" 75 cents a share, but your comment ignores that giving up 50% of the future sales would require that the acquiring company pay ACTC something good. They wouldn't give them those revenues for nothing. So using your methodology, ACTC would be worth (a) 75 cents PLUS (b) the value of what they got for selling half their income and revenue stream. Maybe that wouldn't be $1.50 (using your number) but it would be something significantly more than 75 cents.
    Aug 7 05:36 PM | 1 Like Like |Link to Comment
  • Cheniere Energy seeking $1.9B increase in stock for executives [View news story]
    Seems like Souki has gotten enough for now...should give it a rest.
    May 30 11:35 AM | 7 Likes Like |Link to Comment
  • Cheniere Energy, Inc. Reports First Quarter 2014 Results [View article]
    Has anything changed since an analyst put a $78 price target on this a few weeks ago? Its not priced based on current sales or earnings.

    Maybe there is a price at which this golden goose becomes too rich, but $57 is not it.
    May 1 08:18 PM | 1 Like Like |Link to Comment
  • WSJ's Apple / Comcast Story Not Accurate, News Being Overblown On Wall Street [View article]
    In this day and age its hard to conceive of an American adult who opines on complex business issues but can say "I have never bought, sold or traded a single share of stock in any public company ever. "

    So you keep your money in bitcoins? A checking account? Gold coins? CD's? Cash under the mattress?
    Mar 24 07:57 PM | 8 Likes Like |Link to Comment
  • Advanced Cell Technology: Look For A Breakthrough In 2014 [View article]
    Lots of companies screw up their accounting for stock options. A few years ago, Steve Jobs was called on the carpet for Apple's treatment of stock options (you could look it up!). What's important to recognize is that this company does not trade on book value or earnings per share or anything that is affected by this correction of prior results. There is no net cash effect. This is a big non-issue.

    What counts for investors in this stock are (1) will their FDA trials for AMD and Stargardts be successful and will they get approval, (2) might they be close to ending their initial trials already, and could they get breakthrough treatment from FDA, (3) will a large pharmaceutical company come along and throw money at them (buyout or partnership)? If any of these happen, the stock will FLY.
    Mar 11 03:05 PM | 2 Likes Like |Link to Comment
  • Advanced Cell Technology: Look For A Breakthrough In 2014 [View article]
    I am not the expert, but many people think FDA might grant "breakthrough" status for this treatment before further testing, allowing the treatment to be commercialized immediately. The trial now coming to an end has already provided evidence of efficacy and the treatment is sorely needed by large numbers of people who cannot afford to wait (and no other treatment exists).
    Mar 5 03:32 PM | Likes Like |Link to Comment
  • Bloomberg: New Apple TV set-top on tap, TWC talks ongoing [View news story]
    I'm a cable TV with DVR customer, not a Netflix person.

    A deal with a link to a big content supplier could be interesting. There is great discontent with providers and their high and ever increasing prices. So it wouldn't take much to get me to switch providers.
    Feb 12 04:01 PM | 1 Like Like |Link to Comment
  • Advanced Cell Technology: Look For A Breakthrough In 2014 [View article]
    I assume you were mocking me, but it does seem we are due for some announcement about this study soon, and I do think there will be a media frenzy if the study results are positive. Maybe it won't be Monday night, but it does seem like it should be soon.

    I've been a buyer and holder of ACTC for almost a year, and the stock has done nothing until now. Still, I've been biding my time until these results were announced. Meantime, I've watched the marijuana stocks fly with little or no obvious prospects for profits, based solely on hopes and prayers. Look at the charts for MJNA and PHOT, two stocks I've been following. I'm hoping for a similar response from ACTC if and when we get some good news.
    Jan 30 09:01 PM | 1 Like Like |Link to Comment
COMMENTS STATS
147 Comments
369 Likes